Mental illness, challenging behaviour, and psychotropic ...€¦ · Ilyas, S., & Moncrieff, J....
Transcript of Mental illness, challenging behaviour, and psychotropic ...€¦ · Ilyas, S., & Moncrieff, J....
![Page 1: Mental illness, challenging behaviour, and psychotropic ...€¦ · Ilyas, S., & Moncrieff, J. (2012). Trends in prescrip8ons and costs of drugs for mental disorders in England,](https://reader034.fdocuments.us/reader034/viewer/2022051921/600f0fda9d69cd5d706f449c/html5/thumbnails/1.jpg)
Mental illness, challenging behaviour, and psychotropic drug prescribing in people with intellectual disability: UK population based cohort study Sheehan, R., Hassiotis, A., Walters, K., Osborn, D., Strydom, A., Horsfall, L. Presented by: Tayla McCloud, Rakhi Gupta, Lucy Sutton
![Page 2: Mental illness, challenging behaviour, and psychotropic ...€¦ · Ilyas, S., & Moncrieff, J. (2012). Trends in prescrip8ons and costs of drugs for mental disorders in England,](https://reader034.fdocuments.us/reader034/viewer/2022051921/600f0fda9d69cd5d706f449c/html5/thumbnails/2.jpg)
Intellectual Disability (ID)
● What is it? ○ Also known as learning disabilities ○ A significant deficit in cognitive and adaptive
functioning ○ Onset during the developmental period (DSM-5;
APA, 2013)
○ Causes are often unknown, and differ widely between cases.
![Page 3: Mental illness, challenging behaviour, and psychotropic ...€¦ · Ilyas, S., & Moncrieff, J. (2012). Trends in prescrip8ons and costs of drugs for mental disorders in England,](https://reader034.fdocuments.us/reader034/viewer/2022051921/600f0fda9d69cd5d706f449c/html5/thumbnails/3.jpg)
● Why is it important? ○ Around 1.4 million people in the UK have some form of
learning disability
○ 210,000 have a severe learning disability
○ 80% of these are not known to services (Dept. of Health, 2001).
○ Prevalence of mental illness: 28%, vs. 23% in the general population (Department of Health, 2001; Singleton et al., 2003)
○ Other difficulties: atypical presentation, communication difficulties and problems accessing services.
Intellectual Disability (ID)
![Page 4: Mental illness, challenging behaviour, and psychotropic ...€¦ · Ilyas, S., & Moncrieff, J. (2012). Trends in prescrip8ons and costs of drugs for mental disorders in England,](https://reader034.fdocuments.us/reader034/viewer/2022051921/600f0fda9d69cd5d706f449c/html5/thumbnails/4.jpg)
Challenging behaviour (CB)
• What is it? – Behaviour of an intensity, frequency, or duration
that threatens the physical safety of the person or others, or which restricts access to community facilities for the person or others (Emerson et al., 1995).
![Page 5: Mental illness, challenging behaviour, and psychotropic ...€¦ · Ilyas, S., & Moncrieff, J. (2012). Trends in prescrip8ons and costs of drugs for mental disorders in England,](https://reader034.fdocuments.us/reader034/viewer/2022051921/600f0fda9d69cd5d706f449c/html5/thumbnails/5.jpg)
• Management – Personalised – Behavioural strategies - reinforcement schedules, carer
training, modification of environmental triggers (NICE, 2015)
– Medication, restraint, supported accommodation. • In those with ID
– Around 12.5% show CB (Smiley et al., 2005). – Mental illness, physical illness, stress, need for attention – More difficult to interpret the more severe the ID.
Challenging behaviour (CB)
![Page 6: Mental illness, challenging behaviour, and psychotropic ...€¦ · Ilyas, S., & Moncrieff, J. (2012). Trends in prescrip8ons and costs of drugs for mental disorders in England,](https://reader034.fdocuments.us/reader034/viewer/2022051921/600f0fda9d69cd5d706f449c/html5/thumbnails/6.jpg)
Daniel
![Page 7: Mental illness, challenging behaviour, and psychotropic ...€¦ · Ilyas, S., & Moncrieff, J. (2012). Trends in prescrip8ons and costs of drugs for mental disorders in England,](https://reader034.fdocuments.us/reader034/viewer/2022051921/600f0fda9d69cd5d706f449c/html5/thumbnails/7.jpg)
Antipsychotics
• What are they?
– Drugs which aim to treat psychotic disorders
– Block dopamine receptors
– Require regular monitoring as a result of side effect profile.
• 30-50% of all psychotropics prescribed for those with ID are antipsychotics (Tsiouris, 2010)
• Clients report negative cognitive and emotional effects, mostly owing to side effect profile (Moritz et al., 2013).
![Page 8: Mental illness, challenging behaviour, and psychotropic ...€¦ · Ilyas, S., & Moncrieff, J. (2012). Trends in prescrip8ons and costs of drugs for mental disorders in England,](https://reader034.fdocuments.us/reader034/viewer/2022051921/600f0fda9d69cd5d706f449c/html5/thumbnails/8.jpg)
• Challenging behaviour – Can be used to manage aggressive behaviour associated
with psychotic features (NICE, 2015) – Little to no evidence of efficacy in managing CB independent
of psychotic symptoms (Brylewski et al., 2004). • Recommended by NICE for CB in ID if:
– other CB interventions fail – treatment for any coexisting health problems do not produce improvements
– the risk to the person or others is severe.
Antipsychotics and CB
![Page 9: Mental illness, challenging behaviour, and psychotropic ...€¦ · Ilyas, S., & Moncrieff, J. (2012). Trends in prescrip8ons and costs of drugs for mental disorders in England,](https://reader034.fdocuments.us/reader034/viewer/2022051921/600f0fda9d69cd5d706f449c/html5/thumbnails/9.jpg)
Why does this matter?
• Quality of life for those with ID – Short-term side effects – Serious long-term side effects – Effects on learning and cognitive abilities (Aman et al.,
1984). • Diagnostic overshadowing
– Prevalence of psychosis is estimated at around 3% (Smiley et al., 2005)
– Other health problems left untreated.
![Page 10: Mental illness, challenging behaviour, and psychotropic ...€¦ · Ilyas, S., & Moncrieff, J. (2012). Trends in prescrip8ons and costs of drugs for mental disorders in England,](https://reader034.fdocuments.us/reader034/viewer/2022051921/600f0fda9d69cd5d706f449c/html5/thumbnails/10.jpg)
• Evidence-based medicine – Lack of evidence of efficacy in CB in ID (Brylewski et al.,
2004)
– Lack of evidence of long-term effects of antipsychotic prescription in those with ID
– RCT evidence: no significant benefit over placebo (Tyrer et al., 2008)
Why does this matter?
![Page 11: Mental illness, challenging behaviour, and psychotropic ...€¦ · Ilyas, S., & Moncrieff, J. (2012). Trends in prescrip8ons and costs of drugs for mental disorders in England,](https://reader034.fdocuments.us/reader034/viewer/2022051921/600f0fda9d69cd5d706f449c/html5/thumbnails/11.jpg)
Objective of the Study
● the incidence of recorded mental illness & CB in people with ID in UK primary care
● to explore the prescription of psychotropic drugs
![Page 12: Mental illness, challenging behaviour, and psychotropic ...€¦ · Ilyas, S., & Moncrieff, J. (2012). Trends in prescrip8ons and costs of drugs for mental disorders in England,](https://reader034.fdocuments.us/reader034/viewer/2022051921/600f0fda9d69cd5d706f449c/html5/thumbnails/12.jpg)
Methodology
• Cohort study: 1999 to 2013 • Datasource: The Health Improvement Network (THIN) • primary care database- more than 3.7 million active patients in 571 general practices • GP hospital based specialists inf. stored in computerised system as Read codes (standardised clinical terms based on a hierarchical system) • contains symptoms, diagnoses, referrals to secondary care, record of treatments and of prescriptions, patients’ demographic information
![Page 13: Mental illness, challenging behaviour, and psychotropic ...€¦ · Ilyas, S., & Moncrieff, J. (2012). Trends in prescrip8ons and costs of drugs for mental disorders in England,](https://reader034.fdocuments.us/reader034/viewer/2022051921/600f0fda9d69cd5d706f449c/html5/thumbnails/13.jpg)
Inclusion Criteria Identified by QOF (quality and outcomes framework) ID codes and Read codes signalling ID. Age 18+ Exclusion Criteria people who contributed less than 12 months’ data to THIN
Methodology
![Page 14: Mental illness, challenging behaviour, and psychotropic ...€¦ · Ilyas, S., & Moncrieff, J. (2012). Trends in prescrip8ons and costs of drugs for mental disorders in England,](https://reader034.fdocuments.us/reader034/viewer/2022051921/600f0fda9d69cd5d706f449c/html5/thumbnails/14.jpg)
Outcomes of interest
![Page 15: Mental illness, challenging behaviour, and psychotropic ...€¦ · Ilyas, S., & Moncrieff, J. (2012). Trends in prescrip8ons and costs of drugs for mental disorders in England,](https://reader034.fdocuments.us/reader034/viewer/2022051921/600f0fda9d69cd5d706f449c/html5/thumbnails/15.jpg)
Statistic Analysis Multivariable mixed Poisson regression • time trends of MI & PD • incidence rate ratios • factors associated with CB & antipsychotic drugs • multiplicative interactions between sex, CB, and prescription of antipsychotics Wald tests • significance for categorical variables and categorical interaction terms. • P value of 0.05 to be statistically significant (two tailed)
![Page 16: Mental illness, challenging behaviour, and psychotropic ...€¦ · Ilyas, S., & Moncrieff, J. (2012). Trends in prescrip8ons and costs of drugs for mental disorders in England,](https://reader034.fdocuments.us/reader034/viewer/2022051921/600f0fda9d69cd5d706f449c/html5/thumbnails/16.jpg)
Results
• 33 016 people met the inclusion criteria (58% male) • Average age at study entry: 36.3 years • Median follow-up time was 5.5 (interquartile range 2.2-11.5) years
![Page 17: Mental illness, challenging behaviour, and psychotropic ...€¦ · Ilyas, S., & Moncrieff, J. (2012). Trends in prescrip8ons and costs of drugs for mental disorders in England,](https://reader034.fdocuments.us/reader034/viewer/2022051921/600f0fda9d69cd5d706f449c/html5/thumbnails/17.jpg)
Percentage Description
![Page 18: Mental illness, challenging behaviour, and psychotropic ...€¦ · Ilyas, S., & Moncrieff, J. (2012). Trends in prescrip8ons and costs of drugs for mental disorders in England,](https://reader034.fdocuments.us/reader034/viewer/2022051921/600f0fda9d69cd5d706f449c/html5/thumbnails/18.jpg)
NewrecordingsofCB significantly more common in people
• older than 50 years • with mental illness (including severe mental
illness, depression, and anxiety), autism, dementia, and epilepsy
Positive association b/w CB and degree of ID
Results
![Page 19: Mental illness, challenging behaviour, and psychotropic ...€¦ · Ilyas, S., & Moncrieff, J. (2012). Trends in prescrip8ons and costs of drugs for mental disorders in England,](https://reader034.fdocuments.us/reader034/viewer/2022051921/600f0fda9d69cd5d706f449c/html5/thumbnails/19.jpg)
Psychotropic drugs
Time trends in new prescriptions of psychotropic drugs in adults with intellectual disability in UK primary care, 1999-2013
![Page 20: Mental illness, challenging behaviour, and psychotropic ...€¦ · Ilyas, S., & Moncrieff, J. (2012). Trends in prescrip8ons and costs of drugs for mental disorders in England,](https://reader034.fdocuments.us/reader034/viewer/2022051921/600f0fda9d69cd5d706f449c/html5/thumbnails/20.jpg)
Relations between recorded severe mental illness, CB, and prescription of antipsychotic drugs in adults with ID
71%-no record of severe mental illness
26%- no severe mental illness, No CB
![Page 21: Mental illness, challenging behaviour, and psychotropic ...€¦ · Ilyas, S., & Moncrieff, J. (2012). Trends in prescrip8ons and costs of drugs for mental disorders in England,](https://reader034.fdocuments.us/reader034/viewer/2022051921/600f0fda9d69cd5d706f449c/html5/thumbnails/21.jpg)
Conclusions
● Prescription of psychotropic drugs without any record of CB & MI
● Antipsychotics- often prescribed for CB
![Page 22: Mental illness, challenging behaviour, and psychotropic ...€¦ · Ilyas, S., & Moncrieff, J. (2012). Trends in prescrip8ons and costs of drugs for mental disorders in England,](https://reader034.fdocuments.us/reader034/viewer/2022051921/600f0fda9d69cd5d706f449c/html5/thumbnails/22.jpg)
Strengths
•TheTHINdatabaseisarecordofreallifeclinicalprac8ceinUKprimarycare,andthereforeprovidesanaccurateinsightintocontemporarycare
•THINisrepresenta8veoftheUKpopula8onintermsofdemographicsandcrudeprevalenceofmajorcondi8ons(Blaketal,2011)
•Providesrou8nelycollecteddataforpeoplewithID,whomayotherwisebedifficulttostudy
![Page 23: Mental illness, challenging behaviour, and psychotropic ...€¦ · Ilyas, S., & Moncrieff, J. (2012). Trends in prescrip8ons and costs of drugs for mental disorders in England,](https://reader034.fdocuments.us/reader034/viewer/2022051921/600f0fda9d69cd5d706f449c/html5/thumbnails/23.jpg)
Limitations
Sample •May be over-representative of higher socioeconomic groups or people with
more engaged carers •Younger patients were excluded (<18 years old) •Mild cases of ID may have been missed •No control group of people without ID
![Page 24: Mental illness, challenging behaviour, and psychotropic ...€¦ · Ilyas, S., & Moncrieff, J. (2012). Trends in prescrip8ons and costs of drugs for mental disorders in England,](https://reader034.fdocuments.us/reader034/viewer/2022051921/600f0fda9d69cd5d706f449c/html5/thumbnails/24.jpg)
MeasuresIntellectual disability •doesn’t include diagnoses that may have been entered in free text on the computer
system •Certain characteristics of ID (e.g. severity) are not always well recorded
Neuropsychiatric disorders •Restricted mental illness code lists – exclusion of categories such as personality
disorder and substance misuse
![Page 25: Mental illness, challenging behaviour, and psychotropic ...€¦ · Ilyas, S., & Moncrieff, J. (2012). Trends in prescrip8ons and costs of drugs for mental disorders in England,](https://reader034.fdocuments.us/reader034/viewer/2022051921/600f0fda9d69cd5d706f449c/html5/thumbnails/25.jpg)
Challenging behaviour •challenging behaviour code list has not been externally validated
Psychotropic drugs •only recorded prescriptions given by GPs •cannot establish with certainty the reason for prescribing medication
Measures
![Page 26: Mental illness, challenging behaviour, and psychotropic ...€¦ · Ilyas, S., & Moncrieff, J. (2012). Trends in prescrip8ons and costs of drugs for mental disorders in England,](https://reader034.fdocuments.us/reader034/viewer/2022051921/600f0fda9d69cd5d706f449c/html5/thumbnails/26.jpg)
Clinical Implications Implications for the individual and for healthcare systems •Adverse side effects •Risk of drug-drug interactions •Difficulty with patients who lack the capacity to consent to drug treatment
- Therefore it is important that family/carers are provided with adequate information regarding the use of psychotropic drugs and availability of other means of treatment and support
•Burden of avoidable costs to healthcare services in terms of supplying the drugs and additional monitoring of patients
![Page 27: Mental illness, challenging behaviour, and psychotropic ...€¦ · Ilyas, S., & Moncrieff, J. (2012). Trends in prescrip8ons and costs of drugs for mental disorders in England,](https://reader034.fdocuments.us/reader034/viewer/2022051921/600f0fda9d69cd5d706f449c/html5/thumbnails/27.jpg)
Future research and areas of focus Qualitative research should be conducted to address the following: 1. Why most antipsychotics are prescribed to people without a record of severe mental illness 2. Why so many people with challenging behaviour receive antipsychotics.
Additional research should aim to: 1. Expand the evidence base for the use of drug treatment in people with ID 2. Improve accessibility and development of alternative strategies to managing challenging behaviour
![Page 28: Mental illness, challenging behaviour, and psychotropic ...€¦ · Ilyas, S., & Moncrieff, J. (2012). Trends in prescrip8ons and costs of drugs for mental disorders in England,](https://reader034.fdocuments.us/reader034/viewer/2022051921/600f0fda9d69cd5d706f449c/html5/thumbnails/28.jpg)
What else can be done? • Ensure carers and patients are educated about particular drug treatments and the
availability of alternative interventions • Try to improve the accuracy and time taken to diagnose mental illness in people with ID • Conduct medicine optimization programs for people with ID who are taking these
psychotropic drugs
- Improve their outcomes
- Take their medication correctly
- Avoid taking unnecessary medicines
- Improve medicine safety
- Consider opportunities for lifestyle changes and nonmedical therapies
Future research and areas of focus
![Page 29: Mental illness, challenging behaviour, and psychotropic ...€¦ · Ilyas, S., & Moncrieff, J. (2012). Trends in prescrip8ons and costs of drugs for mental disorders in England,](https://reader034.fdocuments.us/reader034/viewer/2022051921/600f0fda9d69cd5d706f449c/html5/thumbnails/29.jpg)
ReferencesAmericanPsychiatricAssocia8on.Diagnos8candsta8s8calmanualofmentaldisorders.5thed.Arlington:AmericanPsychiatricPublishing;2013.
Brylewski,J.,&Duggan,L.(2004).An8psycho8cmedica8onforchallengingbehaviourinpeoplewithlearningdisability.CochraneDatabaseofSystema2cReviews,3.
Deb,S.,Kwok,H.,Bertelli,M.,Salvador-Carulla,L.,Bradley,E.,Torr,J.,&Barnhill,J.(2009).Interna8onalguidetoprescribingpsychotropicmedica8onforthemanagementofproblembehavioursinadultswithintellectualdisabili8es.WorldPsychiatry,8(3),181-186.
DepartmentofHealth.(2001).ValuingPeople:ANewStrategyforLearningDisabilityforthe21stCentury(Cm5086).Emerson,E.(1995).Challengingbehaviour:Analysisandinterven2oninpeoplewithlearningdisabili2es.CambridgeUniversityPress,40West20thStreet,NewYork,NY10011-4211.
Ilyas,S.,&Moncrieff,J.(2012).Trendsinprescrip8onsandcostsofdrugsformentaldisordersinEngland,1998–2010.TheBri2shJournalofPsychiatry,200(5),393-398.
Linaker.O.M.(1990).Frequencyanddeterminantsforpsychotropicdruguseinanins8tu8onforthementallyretarded.Bri2shJournalofPsychiatry,156(4),525–530.
Moritz,S.,Andreou,C.,Klingberg,S.,Thoering,T.,&Peters,M.J.(2013).Assessmentofsubjec8vecogni8veandemo8onaleffectsofan8psycho8cdrugs.Effectbydefect?.Neuropharmacology,72,179-186.
![Page 30: Mental illness, challenging behaviour, and psychotropic ...€¦ · Ilyas, S., & Moncrieff, J. (2012). Trends in prescrip8ons and costs of drugs for mental disorders in England,](https://reader034.fdocuments.us/reader034/viewer/2022051921/600f0fda9d69cd5d706f449c/html5/thumbnails/30.jpg)
Molyneux,P.,Emerson,E.,&Caine,A.(1999).Prescrip8onofPsychotropicMedica8ontoPeoplewithIntellectualDisabili8esinPrimaryHealth-careSejngs.JournalofAppliedResearchinIntellectualDisabili2es,12(1),46-57.
Na8onalIns8tuteforHealthandClinicalExcellence.(2014).Psychosisandschizophreniainadults:preven8onandmanagement.NICEguidelinesCG178[internet].London:Na8onalIns8tuteforHealthandClinicalExcellence.Availablefrom:hnps://www.nice.org.uk/guidance/cg178.
Na8onalIns8tuteforHealthandClinicalExcellence.(2015).Challengingbehaviourandlearningdisabili8es:preven8onandinterven8onsforpeoplewithlearningdisabili8eswhosebehaviourchallenges.NICEguidelinesNG11[internet].London:Na8onalIns8tuteforHealthandClinicalExcellence.Availablefrom:hnps://www.nice.org.uk/Guidance/NG11.
Singleton,N.,Bumpstead,R.,O'Brien,M.,Lee,A.,&Meltzer,H.(2003).Psychiatricmorbidityamongadultslivinginprivatehouseholds,2000.Interna2onalReviewofPsychiatry,15(1-2),65-73.
Smiley,E.(2005).Epidemiologyofmentalhealthproblemsinadultswithlearningdisability:anupdate.Advancesinpsychiatrictreatment,11(3),214-222.
Tsiouris,J.A.(2010).Pharmacotherapyforaggressivebehavioursinpersonswithintellectualdisabili8es:treatmentormistreatment?JournalofIntellectualDisabilityResearch,54(1),1-16.
Tyrer,P.,Oliver-Africano,P.C.,Ahmed,Z.,Bouras,N.,Cooray,S.,Deb,S.,...&Kramo,K.(2008).Risperidone,haloperidol,andplacebointhetreatmentofaggressivechallengingbehaviourinpa8entswithintellectualdisability:arandomisedcontrolledtrial.TheLancet,371(9606),57-63.